Skip to main content
New product approved
for adults with major depressive disorder
     view press release

intellectual
property

a broad portfolio to meet patient needs.

a broad portfolio to meet patient needs.

Our intellectual property portfolio currently provides protection extending through 2040.

Our intellectual property portfolio currently provides protection extending through 2040.

AXS-05

>60 Issued U.S. Patents
>50 Issued O-U.S. Patents
Claims extending to
at least 2040
Multiple pending

Proprietary manufacturing
Drug Product Formulation

AXS-07

>50 Issued U.S. Patents
>40 Issued O-U.S. Patents
Claims extending to
at least 2036
Multiple pending

Proprietary manufacturing
Drug Product Formulation

AXS-12

1 Issued U.S. Patent
Multiple pending U.S. Patents
Orphan Drug Designation

AXS-14

Multiple pending U.S. Patents